Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Science, Shiraz, Iran.
Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
PLoS One. 2021 Feb 10;16(2):e0246752. doi: 10.1371/journal.pone.0246752. eCollection 2021.
Among cancer treatment methods, targeted therapy using cancer-associated biomarkers has minimum side effects. Recently olfactory receptor (OR) family attracts the researcher's attention as a favorable biomarker of cancer. Here, a statistical approach using complete data from the human protein atlas database was used to evaluate the potential of OR51J1 gene as a cancer-associated biomarker. To confirm the findings of statistical analysis, the OR51J1 mRNA and protein expression levels in breast tumor and normal tissue were measured using quantitative Real Time PCR (qRT-PCR) and immunohistochemistry (IHC) techniques. The association with clinicopathological factors was analyzed. Statistical analysis revealed that OR51J1 has a high expression level in more than 20 types of cancer tissues without any expression in 44 normal tissues. In 15 cancer types, including breast cancer, expression score was more than 90%. The qRT-PCR analysis in breast cancer showed OR51J1 have significantly higher expression level in tumors than normal tissues (2.91 fold). The IHC results showed OR51J1 expression on other cellular subtypes than tumor and normal cells, including myoepithelium, fibroblast, and lymphocytes. OR51J1 protein expression in invasive cells, as well as its overall score, showed a significant correlation with ER and PR expression and breast cancer (BC) subtypes. Results revealed the potential of OR51J1 as a cancer-associated biomarker for the diagnosis of breast cancer at the mRNA level.
在癌症治疗方法中,使用癌症相关生物标志物的靶向治疗具有最小的副作用。最近,嗅觉受体 (OR) 家族作为癌症的有利生物标志物引起了研究人员的关注。在这里,使用人类蛋白质图谱数据库中的完整数据使用统计方法来评估 OR51J1 基因作为癌症相关生物标志物的潜力。为了确认统计分析的结果,使用定量实时 PCR (qRT-PCR) 和免疫组织化学 (IHC) 技术测量了乳腺癌和正常组织中 OR51J1 mRNA 和蛋白质的表达水平。分析了与临床病理因素的关联。统计分析表明,OR51J1 在 20 多种癌症组织中具有高表达水平,而在 44 种正常组织中没有表达。在包括乳腺癌在内的 15 种癌症类型中,表达评分超过 90%。乳腺癌的 qRT-PCR 分析表明,OR51J1 在肿瘤中的表达水平明显高于正常组织(2.91 倍)。IHC 结果表明,OR51J1 在肿瘤细胞以外的其他细胞亚型上表达,包括肌上皮细胞、成纤维细胞和淋巴细胞。OR51J1 蛋白在浸润细胞中的表达及其总评分与 ER 和 PR 表达以及乳腺癌 (BC) 亚型呈显著相关。结果表明,OR51J1 具有作为乳腺癌诊断的癌症相关生物标志物的潜力,可在 mRNA 水平上进行诊断。